🎉 Let’s start 2023 with good news: The FDA Modernization Act 2.0 has passed congress and is inked by President Biden! 🧫 This big achievement lets the FDA consider non-animal cutting-edge testing methods as standalone tests for preclinical studies, finally allowing the use Organs-on-Chip and NAMs for drug safety and efficacy assessment. 📑 𝘛𝘩𝘦 𝘍𝘋𝘈...

🏆 Congratulations to Aude Rapet for receiving the ecopa Award at the European Society of Toxicology in Vitro ESTIV Congress!!! We kindly thank the awarding committee, Costanza Rovida and Stefano Lorenzetti, for the recognition of this work, in which Aude presented the AXbreathing lung-on-chip use case in toxicology and drug testing with a focus on 3R and regulatory submission.   🙏 Thank you...

⭐️ Did you miss the EUSAAT congress last month? 👀 If you did, here is your chance to catch up! Check out this insightful summary of the latest technologies and research to replace animals shown during the congress. 🙏 Thanks Menschen Für Tierrechte for the highlight.

📢 As of Sept 29, the FDA Modernization Act 2.0 has passed the US Senate. 💡This bill marks a turning point in how animal testing is seen in drug development.  By stating that innovative technologies such as Organs-on-Chip and microphysiological systems can be used to evaluate drug safety and efficacy, the bill enables relevant validated...